Vigil Neuroscience (VIGL) Stock Forecast, Price Target & Predictions
VIGL Stock Forecast
Vigil Neuroscience stock forecast is as follows: an average price target of $11.00 (represents a 199.73% upside from VIGL’s last price of $3.67) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
VIGL Price Target
The average price target for Vigil Neuroscience (VIGL) is $11.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 199.73% upside from VIGL's last price of $3.67.
VIGL Analyst Ratings
According to 3 Wall Street analysts, Vigil Neuroscience's rating consensus is 'Buy'. The analyst rating breakdown for VIGL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vigil Neuroscience Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Paul Matteis | Stifel Nicolaus | $11.00 | $3.12 | 252.02% | 199.73% |
The latest Vigil Neuroscience stock forecast, released on Aug 15, 2024 by Paul Matteis from Stifel Nicolaus, set a price target of $11.00, which represents a 252.02% increase from the stock price at the time of the forecast ($3.12), and a 199.73% increase from VIGL last price ($3.67).
Vigil Neuroscience Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $11.00 | $11.00 |
| Last Closing Price | $3.67 | $3.67 | $3.67 |
| Upside/Downside | -100.00% | 199.73% | 199.73% |
In the current month, the average price target of Vigil Neuroscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vigil Neuroscience's last price of $3.67. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Guggenheim | Buy | Buy | Hold |
| Jun 28, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Vigil Neuroscience's last stock rating was published by Guggenheim on Aug 14, 2024. The company gave VIGL a "Buy" rating, the same as its previous rate.
Vigil Neuroscience Financial Forecast
Vigil Neuroscience Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VIGL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vigil Neuroscience EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VIGL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vigil Neuroscience's previous annual EBITDA (undefined) of $NaN.
Vigil Neuroscience Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-19.61M | $-19.20M | $-18.79M | $-21.09M | $-22.87M | $-22.11M | $-22.33M |
| High Forecast | $-19.61M | $-19.20M | $-18.79M | $-21.09M | $-22.87M | $-18.49M | $-22.33M |
| Low Forecast | $-19.61M | $-19.20M | $-18.79M | $-21.09M | $-22.87M | $-26.53M | $-22.33M |
| Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VIGL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vigil Neuroscience SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VIGL last annual SG&A of $NaN (undefined).
Vigil Neuroscience EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.48 | $-0.47 | $-0.46 | $-0.52 | $-0.56 | $-0.55 | $-0.55 |
| High Forecast | $-0.48 | $-0.47 | $-0.46 | $-0.52 | $-0.56 | $-0.46 | $-0.55 |
| Low Forecast | $-0.48 | $-0.47 | $-0.46 | $-0.52 | $-0.56 | $-0.65 | $-0.55 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vigil Neuroscience's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VIGL previous annual EPS of $NaN (undefined).
Vigil Neuroscience Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| OPT | Opthea | $3.15 | $14.00 | 344.44% | Buy |
| PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
| VIGL | Vigil Neuroscience | $3.67 | $11.00 | 199.73% | Buy |
| PRTC | PureTech Health | $19.62 | $57.00 | 190.52% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| TRDA | Entrada Therapeutics | $15.00 | $18.00 | 20.00% | Buy |
| THRD | Third Harmonic Bio | $13.57 | $16.15 | 19.01% | Buy |
| TYRA | Tyra Biosciences | $21.24 | $25.00 | 17.70% | Buy |
VIGL Forecast FAQ
Is Vigil Neuroscience a good buy?
Yes, according to 3 Wall Street analysts, Vigil Neuroscience (VIGL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of VIGL's total ratings.
What is VIGL's price target?
Vigil Neuroscience (VIGL) average price target is $11 with a range of $11 to $11, implying a 199.73% from its last price of $3.67. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vigil Neuroscience stock go up soon?
According to Wall Street analysts' prediction for VIGL stock, the company can go up by 199.73% (from the last price of $3.67 to the average price target of $11), up by 199.73% based on the highest stock price target, and up by 199.73% based on the lowest stock price target.
Can Vigil Neuroscience stock reach $6?
VIGL's average twelve months analyst stock price target of $11 supports the claim that Vigil Neuroscience can reach $6 in the near future.
What are Vigil Neuroscience's analysts' financial forecasts?
Vigil Neuroscience's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-67.305M (high $-63.687M, low $-71.726M), average SG&A $0 (high $0, low $0), and average EPS is $-1.659 (high $-1.57, low $-1.768). VIGL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-78.695M (high $-78.695M, low $-78.695M), average SG&A $0 (high $0, low $0), and average EPS is $-1.94 (high $-1.94, low $-1.94).